摘要
目的:探讨维生素D联合Ki67在三阴性乳腺癌(TNBC)化疗后患者预后评估中的应用价值。方法:选取2015年1月至2018年12月我院收治的TNBC患者118例为研究对象,分析维生素D、Ki67与总体生存率(OS)、无瘤生存率(DFS)的相关性,及维生素D联合Ki67在TNBC化疗后患者预后评估中的预测作用。结果:118例TNBC患者血清25-(OH)D与TNBC患者的OS、DFS具有正相关(P<0.05),Ki67与TNBC患者的OS、DFS具有负相关(P<0.05)。COX回归分析中,血清25-(OH)D、TNM分期、淋巴结转移及Ki67是TNBC患者OS、DFS的独立影响因素(P<0.05)。预后评估中,血清25-(OH)D联合Ki67评估OS和DFS的AUC分别是0.901和0.917,均较单一指标评估OS和DFS的AUC高(P<0.05)。结论:维生素D缺乏,Ki67(+)是TNBC患者生存预后的独立危险因素,维生素D联合Ki67可能较单一指标预测TNBC化疗后患者生存预后更准确。
Objective:To explore the value of vitamin D combined with Ki67 in prognosis evaluation of patients with triple negative breast cancer(TNBC)after chemotherapy.Methods:118 patients with TNBC admitted to our hospital from January 2015 to December 2018 were selected as the research objects.The correlation between vitamin D,Ki67 and overall survival rate(OS),tumor-free survival rate(DFS)were analyzed,and the predictive role of vitamin D combined with Ki67 in the prognosis evaluation of patients after TNBC chemotherapy was analyzed.Results:Serum 25-(OH)d was positively correlated with OS and DFS in 118 patients with TNBC(P<0.05),while Ki67 was negatively correlated with OS and DFS(P<0.05).In Cox regression analysis,serum 25-(OH)d,TNM stage,lymph node metastasis and Ki67 were independent influencing factors of OS and DFS in TNBC patients(P<0.05).The AUC of serum 25-(OH)d combined with Ki67 in assessing OS and DFS were 0.901 and 0.917,respectively,which were higher than those of OS and DFS evaluated by single index(P<0.05).Conclusion:Vitamin D deficiency and Ki67(+)are independent risk factors for survival and prognosis of TNBC patients.Vitamin D combined with ki67 may be more accurate in predicting survival and prognosis of patients with TNBC after chemotherapy than a single index.
作者
陈梅林
苏贞绍
颜永清
车建华
CHEN Meilin;SU Zhenshao;YAN Yongqing;CHE Jianhua(Department of Oncology,the First People's Hospital of Qingzhou,Qingzhou 535000,China)
出处
《现代医学》
2020年第8期971-977,共7页
Modern Medical Journal
关键词
三阴性乳腺癌
维生素D
KI67
联合
生存结局
预后评估
triple negative breast cancer
vitamin D
Ki67
combination
survival outcome
prognosis evaluation
